Director Change: Resignation of John Duncan

DIRECTOR CHANGE: RESIGNATION OF JOHN DUNCAN Pacific Edge Limited advises that John Duncan has notified the Board of his resignation as a Director of the company, effective immediately. The Board thanks John for his service and wishes him well. John remains a supportive shareholder in the company. ENDS For more information contact: Chris Gallaher Chairman Pacific Edge Ltd P: +61 417 556 691 OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company's products have been tested and validated in international multi-centre clinical studies. End CA:00342056 For:PEB Type:ADMIN Time:2019-10-02 13:40:18